Search

Displaying results 4701 - 4710 of 10000 in total
  1. Drug

    Pazufloxacin

    go.drugbank.com/drugs/DB11774
    Investigational

    Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).

    Categories: Drugs for Treatment of Tuberculosis
  2. Drug

    Rosmarinic acid

    go.drugbank.com/drugs/DB16865
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Cinitapride

    go.drugbank.com/drugs/DB08810
    Investigational

    Cinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: RILOVER G
  4. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.

  5. Drug

    Curcuma aromatica root oil

    go.drugbank.com/drugs/DB11301
    Approved

    Curcuma aromatica root oil is obtained from the roots of *Curcuma aromatica*, or more commonly called wild tumeric, via steamed distillation. *Curcuma aromatica* belongs to the family Zingiberaceae. … The major constituents of Curcuma aromatica root oil are reported to be camphor, curzerenone, α-turmerone, ar-turmerone and 1,8-cineole [A27219].

  6. Drug

    REP8839

    go.drugbank.com/drugs/DB05224
    Experimental

    REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).

  7. Drug

    XmAb 2513

    go.drugbank.com/drugs/DB06324
    Investigational

    XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. … It has been investigated for the treatment of hodgkin’s lymphoma.

  8. Drug

    NRP290

    go.drugbank.com/drugs/DB06383
    Experimental

    NRP290 is a hydrocodone derivative under investigation for the treatment of pain (moderate to moderately severe).

  9. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    Exenatide was given FDA approval on April 28, 2005[L6106]. It is available as immediate- and extended-release formulations. … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021.

    Products: BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection, BYETTA 5 µG/20 µL SC KULLANIMA HAZIR DOLU ENJEKSİYON KALEMI ICINDE COZELTI, 1.2 ML (60 DOZ)
  10. Drug

    Terguride

    go.drugbank.com/drugs/DB13399
    Experimental

    Categories: Heterocyclic Compounds with 4 or More Rings